Diagnostic Algorithm & Red Flags

NeuroWiki

Diagnostic Algorithm & Red Flags

While pattern recognition localizes the lesion within the motor unit, a systematic diagnostic algorithm transforms that localization into a specific, actionable diagnosis. The evaluation of neuromuscular disease follows a structured sequence: confirming that the problem is neuromuscular, localizing the level of involvement, characterizing the pathophysiology (axonal versus demyelinating, acute versus chronic), and then selecting targeted investigations. Equally important is the recognition of red flag features that signal life-threatening neuromuscular emergencies requiring immediate intervention — respiratory failure from diaphragmatic weakness, bulbar compromise threatening airway protection, and autonomic instability. This topic serves as the practical “what to do next” companion to the Pattern Recognition & Localization overview.

Bottom Line

Five-step algorithm: Confirm neuromuscular localization → identify the level (motor neuron, nerve, NMJ, muscle) → characterize the process (acute/chronic, axonal/demyelinating) → order targeted investigations → synthesize a final diagnosis
History drives diagnosis: Onset, pace of progression, distribution, modalities affected, family history, medications, and toxic exposures define the clinical framework before any test is ordered
Respiratory red flags are the most critical: FVC <20 mL/kg, negative inspiratory force (NIF) worse than –30 cmH₂O, and maximal expiratory pressure (MEP) <40 cmH₂O constitute the 20/30/40 rule for anticipated intubation
Rapid progression over hours to days (GBS, myasthenic crisis, rhabdomyolysis) demands emergent evaluation and often ICU-level monitoring
Drug-induced weakness (statins, corticosteroids, colchicine, immune checkpoint inhibitors) is a common and reversible cause that must be excluded in every evaluation
Electrodiagnostic studies remain the cornerstone extension of the clinical examination and should be pursued in nearly all patients except those with clinically definitive diabetic sensory polyneuropathy

Initial Clinical Assessment

Focused Neuromuscular History

The history is the most powerful diagnostic tool in neuromuscular medicine. A directed approach focuses on five clinical elements that, when combined, narrow the differential substantially before any testing is ordered.

Clinical Element	Key Questions	Diagnostic Implications
Onset & progression	When did symptoms begin? Acute (days), subacute (weeks–months), or chronic (months–years)? Stepwise or continuous?	Acute: GBS, myasthenic crisis; Subacute: CIDP, inflammatory myopathy; Chronic: CMT, muscular dystrophy, SMA; Stepwise: vasculitic neuropathy
Distribution	Proximal, distal, or both? Symmetric or asymmetric? Focal or generalized?	Distal symmetric: toxic/metabolic polyneuropathy; Proximal: myopathy or NMJ; Asymmetric: vasculitis, multifocal motor neuropathy, MND
Modalities affected	Motor only? Sensory? Autonomic? Bulbar? Ocular?	Motor-only: MND, NMJ, myopathy; Sensorimotor: neuropathy; Pure sensory: ganglionopathy; Fatigable: NMJ
Family history	Relatives with gait difficulty, foot deformities, wheelchair use? Consanguinity?	Pes cavus + hammer toes in relatives: CMT; Childhood onset in siblings: SMA, congenital myopathy
Medications & exposures	Statins, chemotherapy, alcohol, colchicine, corticosteroids, checkpoint inhibitors?	Drug-induced myopathy or neuropathy must be excluded in every evaluation

Examination Priorities

The neuromuscular examination should be conducted with the patient in a gown to permit inspection of proximal muscles, trunk, and skin. Key components include:

Strength grading (MRC scale): Test proximal and distal muscle groups systematically; grade 0–5; note pattern (proximal versus distal, symmetric versus asymmetric)
Reflexes: Absent in neuropathy; hyperactive with UMN signs in MND; preserved in myopathy and NMJ disorders until late stages
Sensory examination: Vibration (large fiber, quantitative Rydel-Seiffer tuning fork preferred), pinprick (small fiber), proprioception (sensory ataxia if impaired), monofilament (screening for diabetic neuropathy)
Gait and functional assessment: Heel/toe walking, tandem gait, Gowers sign (proximal weakness), steppage gait (foot drop)
Cranial nerves: Ptosis, diplopia, facial weakness, tongue fasciculations, palatal weakness, jaw jerk
Inspection: Atrophy, fasciculations, scapular winging, pes cavus, hammer toes, skin changes (heliotrope rash, Gottron papules, livedo reticularis)

Bedside Tests

Useful Bedside Maneuvers

Ice pack test (myasthenia gravis): Apply ice to a ptotic eyelid for 2 minutes; improvement of ≥2 mm supports NMJ dysfunction (sensitivity ~80%)
Sustained upgaze (2 minutes): Provokes ptosis or diplopia in NMJ disorders; fatigue is the hallmark
Forced vital capacity (FVC): Bedside spirometry detects respiratory muscle weakness before symptoms manifest; compare upright versus supine (drop >20% suggests diaphragmatic weakness)
Single-breath count test: Ask the patient to count from 1 as far as possible on a single breath; inability to reach 20 correlates with reduced FVC
Phalen and Tinel signs: Screen for median neuropathy at the wrist (carpal tunnel syndrome)
Spurling test: Neck extension with lateral flexion and axial compression reproduces radicular pain; specificity >90% for cervical radiculopathy
Straight leg raise: Reproduces radicular pain in L5 or S1 distribution; positive at <60° is most specific

The Diagnostic Algorithm

The following five-step approach provides a structured framework for evaluating any patient with suspected neuromuscular disease. Each step builds upon the information gathered in the preceding step.

Step-by-Step Diagnostic Framework

Step 1 — Is this neuromuscular? Distinguish lower motor neuron (LMN) patterns from CNS disease (UMN signs without LMN involvement, cortical sensory loss, visual field deficits) and functional neurologic disorder (inconsistency on testing, Hoover sign, give-way weakness, non-anatomic sensory loss). Key: LMN weakness produces hyporeflexia and atrophy; UMN weakness produces hyperreflexia and spasticity without atrophy
Step 2 — Localize within the motor unit. Use the pattern of weakness, reflexes, and sensory findings to identify the level: motor neuron (UMN + LMN, no sensory loss), peripheral nerve (distal weakness, sensory loss, hyporeflexia), NMJ (fatigable proximal/ocular/bulbar weakness, normal reflexes, no sensory loss), or muscle (proximal weakness, preserved reflexes early, no sensory loss, elevated CK)
Step 3 — Characterize the process. Determine temporal course (acute/subacute/chronic), pathophysiology (axonal versus demyelinating via electrodiagnostic studies), and distribution pattern (length-dependent versus multifocal versus proximal). This step critically narrows the differential
Step 4 — Targeted investigations. Based on the localization and characterization, order specific tests: electrodiagnostic studies (nerve conduction studies, EMG, repetitive nerve stimulation), laboratory panels tailored to localization, imaging (MRI spine/muscle, neuromuscular ultrasound), and when indicated, biopsy (nerve, muscle, skin) or genetic testing
Step 5 — Final diagnosis and management plan. Integrate clinical, electrodiagnostic, serologic, and pathologic data. Consider Hickam’s dictum — multiple overlapping diagnoses are common in neuromuscular practice (e.g., diabetic polyneuropathy with superimposed carpal tunnel syndrome and lumbar radiculopathy)

Laboratory Workup by Localization

Test selection should be guided by the clinical and electrodiagnostic localization, not by reflexive panel ordering. The American Academy of Neurology recommends fasting glucose, vitamin B12, and serum protein electrophoresis with immunofixation as the highest-yield tests for all patients with polyneuropathy. Beyond these core tests, further workup should be tailored to the clinical phenotype.

Localization	First-Line Tests	Extended Workup (If Indicated)
Motor neuron	EMG/NCS (widespread denervation across multiple myotomes and body regions); no specific blood biomarker for ALS	Genetic testing (SOD1, C9orf72 for familial ALS; SMN1/SMN2 for SMA); Kennedy disease: androgen receptor CAG repeat; MRI brain/spine to exclude structural mimics
Peripheral nerve	Fasting glucose (or HbA1c, 2-hour GTT), vitamin B12 with methylmalonic acid, SPEP/immunofixation, CBC, CMP, TSH	ANA, anti-Ro/La, ANCA, ESR/CRP, HIV, hepatitis B/C, cryoglobulins, anti-ganglioside antibodies (GM1 for MMN), CSF (albuminocytologic dissociation in CIDP), genetic testing (CMT panel), transthyretin for amyloid neuropathy
Neuromuscular junction	AChR binding antibodies (∼85% sensitivity in generalized MG); CT chest (thymoma)	MuSK antibodies (if AChR-negative), LRP4 antibodies; VGCC antibodies (LEMS); anti-striational antibodies (thymoma association); repetitive nerve stimulation, single-fiber EMG (most sensitive test for NMJ disorders)
Muscle	CK (often >5× normal in inflammatory and dystrophic myopathies), aldolase, LDH, AST/ALT	Myositis-specific antibodies (anti-Jo-1, anti-Mi-2, anti-MDA5, anti-SRP, anti-HMGCR for statin-associated necrotizing myopathy); MRI muscle (edema pattern guides biopsy); muscle biopsy; genetic testing (dystrophin, dysferlin, calpain, mitochondrial DNA)

Red Flags in Neuromuscular Disease

Certain clinical features demand urgent or emergent evaluation because they signal conditions with high morbidity and mortality if not recognized promptly. These red flags should trigger immediate assessment and, in many cases, hospitalization.

Red Flags Requiring Urgent Action

Respiratory compromise: FVC <1 L or <20 mL/kg, orthopnea, use of accessory muscles, paradoxical abdominal breathing (diaphragm weakness), inability to count to 20 on a single breath, FVC drop >20% from upright to supine
Bulbar dysfunction with aspiration risk: Dysarthria, dysphagia, nasal regurgitation, wet/gurgly voice, weak cough, inability to protect the airway — seen in GBS, myasthenic crisis, ALS, and bulbar myopathies
Cardiac involvement: Conduction abnormalities and arrhythmias in muscular dystrophies (Duchenne, Emery-Dreifuss, myotonic dystrophy type 1), mitochondrial myopathies, and GBS; obtain ECG in all patients with new neuromuscular weakness
Rapid progression (hours to days): GBS (ascending paralysis), myasthenic crisis, acute rhabdomyolysis (CK >10,000 IU/L with risk of renal failure), tick paralysis, botulism, acute porphyric neuropathy
Autonomic instability: Labile blood pressure, tachycardia/bradycardia, cardiac arrhythmias, ileus — most commonly seen in GBS (up to 70% of severe cases), acute porphyria, and botulism; requires cardiac monitoring
Neck flexor weakness: Head drop is an ominous sign suggesting severe generalized weakness and impending respiratory failure; associated with MG crisis, ALS, inflammatory myopathy, and advanced neuropathies

When to Hospitalize

The threshold for admission should be low in patients with rapidly progressive neuromuscular weakness. Neuromuscular respiratory failure is frequently underrecognized because standard pulse oximetry remains normal until very late in the course — hypoventilation causes hypercapnia long before hypoxemia develops.

Criteria for Hospital and ICU Admission

ICU admission: FVC <20 mL/kg or declining rapidly (>30% drop over hours); NIF worse than –30 cmH₂O; MEP <40 cmH₂O (the “20/30/40 rule”); active myasthenic or cholinergic crisis; GBS with rapid progression or autonomic instability; acute bulbar failure with aspiration
Monitoring protocol: Serial FVC and NIF every 2–4 hours (more frequently if declining); continuous telemetry for autonomic dysfunction; upright and supine FVC comparison; trend the trajectory — a declining FVC is more important than any single absolute value
Intubation considerations: FVC <15 mL/kg or <1 L; clinical signs of respiratory distress (tachypnea, accessory muscle use, paradoxical breathing); rising PaCO₂; inability to clear secretions; the decision should be clinical and anticipatory rather than delayed until crisis
Avoid in neuromuscular respiratory failure: Non-invasive positive pressure ventilation (BiPAP) as a substitute for intubation in patients with bulbar weakness and aspiration risk; high-flow nasal cannula can mask worsening hypoventilation
Floor admission: Patients with moderate weakness, stable or slowly progressive course, and FVC >25 mL/kg who still require monitoring, IV therapies (IVIG, plasma exchange), or diagnostic workup

Common Diagnostic Pitfalls

Neuromuscular diseases are frequently misdiagnosed, with delays that can range from months to years. Recognizing common pitfalls helps avoid these errors.

Pitfalls and Mimics to Avoid

Functional neurologic disorder (FND) mimicking neuromuscular disease: Give-way or collapsing weakness, inconsistent examination findings (strong with distraction, weak with direct testing), Hoover sign positive, non-dermatomal sensory loss; FND can coexist with organic neuromuscular disease, complicating assessment
Drug-induced weakness: Statins (myalgia, CK elevation, or necrotizing autoimmune myopathy with anti-HMGCR antibodies); corticosteroids (painless proximal weakness with normal CK, typically after weeks of ≥10 mg/day prednisone); colchicine (vacuolar myopathy, often with concurrent neuropathy); immune checkpoint inhibitors (myositis, myasthenia, or overlap syndromes)
Thyroid myopathy: Hypothyroid myopathy (proximal weakness, elevated CK, myoedema, delayed relaxation of reflexes) and hyperthyroid myopathy (proximal wasting, often with associated ophthalmopathy) — check TSH in all patients with unexplained myopathy
Delayed diagnosis of myasthenia gravis: Average diagnostic delay is 1–2 years; MG is commonly misdiagnosed as anxiety or depression (ptosis, fatigue), stroke (acute diplopia, ptosis), MS, or bulbar ALS; key distinguishing features are fluctuation and fatigability
Misdiagnosis of CIDP: Diabetic polyneuropathy is frequently misclassified as CIDP based on overinterpretation of electrodiagnostic findings; this leads to unnecessary immunotherapy; true CIDP demonstrates proximal and distal weakness, areflexia, and acquired demyelinating EDX features
Missing hereditary neuropathy: Adult-onset CMT can present as “idiopathic” neuropathy; clues include pes cavus, hammer toes, insidiously progressive course, family history of “weak ankles,” and uniformly slowed conduction velocities on EDX
Overlooking amyloid neuropathy: Transthyretin amyloidosis presents with progressive sensorimotor polyneuropathy, bilateral carpal tunnel syndrome, lumbar stenosis, and prominent autonomic dysfunction — a treatable condition with RNA silencer therapy if diagnosed early

Electrodiagnostic Studies: When and What to Order

Electrodiagnostic testing (nerve conduction studies and EMG) is considered an extension of the neurologic examination and should be performed in nearly all patients with suspected neuromuscular disease. Key indications and principles include:

Confirm localization: EDX distinguishes neuropathic from myopathic processes and localizes focal lesions (e.g., ulnar neuropathy at the elbow versus wrist)
Axonal versus demyelinating: Axonal loss shows reduced amplitudes with preserved conduction velocities; demyelination shows prolonged distal latencies, slowed conduction velocities, temporal dispersion, and conduction block
Acquired versus hereditary demyelination: Acquired (CIDP, GBS) shows non-uniform slowing with conduction block; hereditary (CMT1) shows uniform, diffuse slowing without conduction block
NMJ testing: Repetitive nerve stimulation (decrement >10% at 2–3 Hz in MG; increment at 20–50 Hz in LEMS) and single-fiber EMG (increased jitter; most sensitive test for NMJ disorders)
Chronicity assessment: EMG reveals acute denervation (fibrillation potentials, appearing 14–21 days after injury) versus chronic reinnervation (large-amplitude, long-duration motor unit potentials)
When to defer: Patients with known diabetic sensory polyneuropathy and no red flag features typically do not require EDX; however, EDX has been shown to change diagnosis and management even in this population

Peripheral Nerve Imaging

When clinical and electrodiagnostic findings are ambiguous, imaging modalities provide complementary diagnostic value.

MRI neurography: Evaluates nerve root and plexus pathology, intraneural masses, contrast enhancement suggesting blood-nerve barrier breakdown (inflammatory neuropathies), and proximal nerve segments inaccessible to ultrasound
Neuromuscular ultrasound: Higher resolution than MRI for superficial peripheral nerves; measures cross-sectional area (enlarged in CIDP, multifocal motor neuropathy, and entrapment neuropathies); dynamic assessment for fasciculations, nerve subluxation, and intraneural vascularity; limited by depth penetration for deep nerves
MRI of muscle: Identifies patterns of edema (active inflammation) and fatty replacement (chronic damage) that guide muscle biopsy site selection and narrow the differential in myopathies

References

Jin PH. Localization and diagnostic evaluation of peripheral nerve disorders. Continuum (Minneap Minn). 2024;30(5):1256-1285.
Barohn RJ, Amato AA. Pattern recognition approach to neuropathy and neuronopathy. Neurol Clin. 2013;31(2):343-361.
London ZN. A structured approach to the diagnosis of peripheral nervous system disorders. Continuum (Minneap Minn). 2020;26(5):1130-1160.
England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing. Neurology. 2009;72(2):185-192.
Lau KHV. Laboratory evaluation of peripheral neuropathy. Semin Neurol. 2019;39(5):531-541.
Mehta P, Dorst J, Engel AG. Neuromuscular junction disorders mimicking myopathy. Muscle Nerve. 2015;52(3):307-314.
Bodofsky EB, Carter GT, England JD. Is electrodiagnostic testing for polyneuropathy overutilized? Muscle Nerve. 2017;55(3):301-304.
Claytor B. Myasthenic crisis. Muscle Nerve. 2023;67(2):141-149.
Rabinstein AA, Wijdicks EFM. Acute neuromuscular respiratory failure. Continuum (Minneap Minn). 2015;21(5):1324-1345.
Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58(6):893-898.
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of CIDP: second revision. J Peripher Nerv Syst. 2021;26(3):242-268.
Gonzalez HL, Hobson-Webb LD. Neuromuscular ultrasound in clinical practice: a review. Clin Neurophysiol Pract. 2019;4:148-163.
Zaidman CM, Seelig MJ, Baker JC, et al. Detection of peripheral nerve pathology: comparison of ultrasound and MRI. Neurology. 2013;80(18):1634-1640.
Dalakas MC. Drug-induced myopathies: a comprehensive review and update. Biomedicines. 2024;12(5):987.
Sheikh S, Alvi U, Engstrom JW, et al. Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med. 2021;10(7):1537.
Nathani D, Spies J, Barnett MH, et al. Nerve biopsy: current indications and decision tools. Muscle Nerve. 2021;64(2):125-139.
Zhou L. Small fiber neuropathy. Semin Neurol. 2019;39(5):570-577.
Skrahina V, Grittner U, Beetz C, et al. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology. Ann Med. 2021;53(1):1787-1796.
Pestronk A, Florence J, Levine T, et al. Sensory exam with a quantitative tuning fork: rapid, sensitive and predictive of SNAP amplitude. Neurology. 2004;62(3):461-464.
Cheshire WP, Freeman R, Gibbons CH, et al. Electrodiagnostic assessment of the autonomic nervous system: a consensus statement. Clin Neurophysiol. 2021;132(2):666-682.